论文部分内容阅读
目的:观察孟鲁司特钠辅助治疗婴幼儿呼吸道合胞病毒毛细支气管炎的疗效及对临床症状、预后的影响。方法:将120例婴幼儿呼吸道合胞病毒毛细支气管炎患儿随机分为观察组62例和对照组58例,均采用相同的综合治疗方法,包括呼吸道管理、抗病毒(利巴韦林或重组人干扰素α-1b)、适量补液、吸氧,糖皮质激素(布地奈德混悬液)、β2受体激动剂(沙丁胺醇溶液)及抗胆碱能药(异丙托溴铵)雾化吸入,止咳、化痰、吸痰等治疗。观察组辅以睡前口服孟鲁司特钠每次4 mg,每日1次,疗程1个月。观察两组临床症状改善情况及疗效,随访6个月观察喘息复发情况。结果:观察组咳嗽、喘息等临床症状消失时间均短于对照组(P<0.05),喘息复发例数少于对照组(P<0.05);观察组总有效率95.2%,对照组82.8%,两组比较差异有统计学意义(P<0.05)。结论:孟鲁司特钠辅助治疗婴幼儿呼吸道合胞病毒毛细支气管炎,能明显改善患儿咳嗽、喘息等临床症状,提高临床疗效,减少或预防喘息复发和哮喘。
Objective: To observe the efficacy of montelukast sodium in the treatment of infantile respiratory syncytial virus bronchiolitis and its effect on clinical symptoms and prognosis. Methods: A total of 120 infants with respiratory syncytial virus bronchiolitis were randomly divided into observation group (62 cases) and control group (58 cases), all using the same comprehensive treatment including respiratory management, anti-virus (ribavirin or recombinant Human interferon alfa-1b), moderate rehydration, oxygen inhalation, glucocorticoid (budesonide suspension), β2 receptor agonist (salbutamol solution) and anticholinergics (ipratropium bromide) Inhalation, cough, phlegm, suction and other treatment. Observation group supplemented with bedtime oral montelukast sodium 4 mg once daily for 1 month. The clinical symptom improvement and curative effect were observed in both groups. The wheezing recurrence was observed after 6 months follow-up. Results: The disappearance time of clinical symptoms such as cough and wheeze in observation group were shorter than those in control group (P <0.05), and the number of wheezing relapse was less than that in control group (P <0.05). The total effective rate was 95.2% in observation group and 82.8% in control group, The difference between the two groups was statistically significant (P <0.05). Conclusion: Montelukast adjuvant treatment of infantile respiratory syncytial virus bronchiolitis can significantly improve the clinical symptoms of children cough, wheezing and improve clinical efficacy, reduce or prevent recurrence of asthma and asthma.